On February 28, the centrally procured drug dequasoline sodium eye drops made its market debut.

On April 25, the paper detailing the long-term follow-up results of the Phase II clinical trial of NL003 was publicly released.

On June 13, the last subject in the NL003 Phase III clinical trial for the indication of resting pain was discharged from the study.

On June 20, the NDA submission for the ulcer indication of NL003 was filed.

On July 12, the New Drug Registration Application for NL003 was officially accepted by the National Medical Products Administration.

On August 15, a systematic review and meta-analysis paper on NL003 for the treatment of chronic ischemic diseases was published in a prestigious European journal.

On August 16, the blinding of the NL003 Phase III clinical trial for resting pain indication was lifted, and the results were consistent with expectations.

On September 26, NL003 passed the drug registration inspection.

October 9: Opening Ceremony for the Shanghai Branch

On December 12, the company was awarded the designation of a postdoctoral research workstation.

June 12: All 242 patients enrolled in the Phase III clinical trial NL003 for the ulcer indication have completed enrollment.

June 15: The main structure of the biopharmaceutical base has been topped out.

July 3: The first OTC product—0.1% (0.4 ml: 0.4 mg) sodium hyaluronate eye drops—has been approved.

August 6: Unblinding of Phase IIb clinical trial data for the company’s NL005 project.

August 10: “Diquafosol Sodium Eye Drops” received the “Drug Registration Certificate.”

September 26: The company passed the pharmaceutical GMP compliance inspection.

November 6: Sodium Diclofenac Eye Drops Successfully Won the Bid in the Ninth Round of National Centralized Drug Procurement.

November 21: The company was approved to establish a postdoctoral innovation and practice base.

December 5: All 302 patients enrolled in the NL003 Phase III clinical trial for the indication of resting pain have completed enrollment.

December 9: The production of the registered batch samples for NL003 has been successfully completed.

April 8: The subsidiary, BioPharmaceutical, signed a general contracting agreement for the construction of an industrialization project for biopharmaceutical products.

June 2: Subsidiary Huonland obtained the registration certificate for moxifloxacin hydrochloride eye drops.

July 15: The first patient has been enrolled in the Phase IIb trial of the NL005 project.

July 20: PET-CT trial launched at Peking Union Medical College Hospital.

August 16: Signed a cooperation agreement with IQVIA for an NL003 commercialization strategy study.

October 23: A research paper related to NL003 was published in the American Heart Journal.

November 7: NORTHLAND Selected as a Constituent Stock of the North Exchange 50 Index

March 30: The company signed a strategic cooperation agreement with Qingsong Pharmaceutical.

July 28: The company obtained Certificate B of the Pharmaceutical Production License.

August 9: The NL005 project completed enrollment of the last patient in the Phase IIa clinical trial.

September 8: The company’s first CDMO project, “Levofloxacin,” has received the Drug Registration Approval.

October 22: The groundbreaking ceremony for the Intelligent Biopharmaceutical Industry Base was held.

November 9: The company has obtained certification under the three ISO systems: ISO9001, ISO45001, and ISO14001.

November 15: The company listed on the Beijing Stock Exchange.

August 28: The investigator meeting for the Phase IIa study of NL005 was held.

November 23: NORTHLAND Holds an Online Roadshow

November 24: NORTHLAND Advances to the Select Tier of the New Third Board

December 24: NORTHLAND was awarded three honors by Wabai.com: "2020 Outstanding Chairman of the New Third Board," "2020 Leading Enterprise in the Medical and Healthcare Industry," and "2020 Secretary of the Board Contribution Award."